| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
1 | AN ACT concerning regulation.
| |||||||||||||||||||
2 | Be it enacted by the People of the State of Illinois,
| |||||||||||||||||||
3 | represented in the General Assembly:
| |||||||||||||||||||
4 | Section 2. The Illinois Optometric Practice Act of 1987 is | |||||||||||||||||||
5 | amended by changing Section 15.1 as follows:
| |||||||||||||||||||
6 | (225 ILCS 80/15.1)
| |||||||||||||||||||
7 | (Section scheduled to be repealed on January 1, 2017)
| |||||||||||||||||||
8 | Sec. 15.1. Diagnostic and therapeutic authority.
| |||||||||||||||||||
9 | (a) For purposes of the Act, "ocular pharmaceutical
agents" | |||||||||||||||||||
10 | means topical anesthetics, topical mydriatics, topical
| |||||||||||||||||||
11 | cycloplegics, topical miotics and mydriatic reversing agents, | |||||||||||||||||||
12 | anti-infective agents,
anti-allergy agents,
anti-glaucoma | |||||||||||||||||||
13 | agents (except oral carbonic anhydrase inhibitors, which may be | |||||||||||||||||||
14 | prescribed only in a quantity sufficient to provide treatment | |||||||||||||||||||
15 | for up to 72 hours),
anti-inflammatory agents (except oral | |||||||||||||||||||
16 | steroids), over-the-counter agents, analgesic
agents, anti-dry | |||||||||||||||||||
17 | eye agents, and agents for the treatment of hypotrichosis. | |||||||||||||||||||
18 | (a-3) In addition to ocular pharmaceutical agents that fall | |||||||||||||||||||
19 | within the categories set forth in subsection (a) of this | |||||||||||||||||||
20 | Section, the Board may add a pharmaceutical agent approved by | |||||||||||||||||||
21 | the FDA or class of agents for the purpose of the diagnosis or | |||||||||||||||||||
22 | treatment of conditions of the eye and adnexa after | |||||||||||||||||||
23 | consideration of the agent's systemic effects, side effects, |
| |||||||
| |||||||
1 | and the use of the agent within the practice of optometry. The | ||||||
2 | Board shall consider requests for additional agents and make | ||||||
3 | recommendations within 90 days after the receipt of the | ||||||
4 | request. | ||||||
5 | Within 45 days after the Board's recommendation to the | ||||||
6 | Department of a pharmaceutical agent or class of agents, the | ||||||
7 | Department shall promulgate rules necessary to allow for the | ||||||
8 | prescribing or administering of the pharmaceutical agent or | ||||||
9 | class of agents under this Act. | ||||||
10 | (a-5) Ocular pharmaceutical agents administered by | ||||||
11 | injection may be used only for the treatment of anaphylaxis. | ||||||
12 | (a-10) Oral pharmaceutical agents may be prescribed for a | ||||||
13 | child under 5 years of age only in consultation with a | ||||||
14 | physician licensed to practice medicine in all its branches. | ||||||
15 | (a-15) The authority to prescribe a Schedule III, IV, or V | ||||||
16 | controlled substance shall include only analgesic agents only | ||||||
17 | in a quantity sufficient to provide treatment for up to 72 | ||||||
18 | hours. The prescription of a Schedule II controlled substance | ||||||
19 | is prohibited , except for Dihydrocodeinone (Hydrocodone) with | ||||||
20 | one or more active, non-narcotic ingredients only in a quantity | ||||||
21 | sufficient to provide treatment for up to 72 hours, and only if | ||||||
22 | such formulations of Dihydrocodeinone are reclassified as | ||||||
23 | Schedule II by the U.S. Food and Drug Administration .
| ||||||
24 | (b) A licensed optometrist may remove superficial foreign | ||||||
25 | bodies from the human eye and adnexa and may give orders for | ||||||
26 | patient care to a nurse licensed to practice under Illinois |
| |||||||
| |||||||
1 | law.
| ||||||
2 | (c) An optometrist's license shall be revoked or suspended | ||||||
3 | by the Department
upon recommendation of the Board based upon | ||||||
4 | either of the
following causes: | ||||||
5 | (1) grave or repeated misuse of any ocular
| ||||||
6 | pharmaceutical agent; and | ||||||
7 | (2) the use of any agent or procedure in the course of | ||||||
8 | optometric practice
by an optometrist not properly | ||||||
9 | authorized under this Act. | ||||||
10 | (d) The Secretary of Financial and Professional Regulation | ||||||
11 | shall notify
the Director of Public Health as to the categories | ||||||
12 | of ocular
pharmaceutical agents permitted for use by an | ||||||
13 | optometrist. The Director of Public Health shall in turn
notify | ||||||
14 | every licensed pharmacist in the State of the categories of | ||||||
15 | ocular
pharmaceutical agents that can be utilized and | ||||||
16 | prescribed by an optometrist.
| ||||||
17 | (Source: P.A. 97-170, eff. 7-22-11.)
|